USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR

BeOne Medicines Ltd.

USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.
Patent is part of infringement lawsuit against BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) filed by Pharmacyclics in 2023.
BeiGene filed PGR petition on November 1, 2023; USPTO decision is appealable by Pharmacyclics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.